Definium Therapeutics, Inc.
Definium Therapeutics, Inc.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||||||||
Assets Current | |||||||||||||||||
Cash And Cash Equivalents At Carrying Value | 263 | 258 | 20 | 33 | 83 | 274 | 295 | 243 | 252 | 100 | 118 | 117 | |||||
Short Term Investments | 111 | 154 | 189 | 150 | 130 | 0 | - | - | - | - | - | - | |||||
Prepaid Expense And Other Assets Current | 7 | 8 | 7 | 6 | 9 | 8 | 4 | 5 | 3 | 4 | 2 | 3 | |||||
Assets Current | 381 | 419 | 216 | 189 | 222 | 282 | 299 | 248 | 255 | 104 | 120 | 120 | |||||
Goodwill | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | |||||
Indefinite Lived Intangible Assets Excluding Goodw… | - | - | - | - | - | - | - | - | - | 1 | 1 | 2 | |||||
Long Term Investments | - | - | - | 55 | 33 | - | - | - | - | - | - | - | |||||
Other Assets Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | |||||
Assets | 401 | 440 | 237 | 265 | 275 | 302 | 320 | 268 | 276 | 125 | 142 | 142 | |||||
Liabilities And Stockhold… | |||||||||||||||||
Liabilities Current | |||||||||||||||||
Accounts Payable Current | 7 | 5 | 8 | 4 | 2 | 2 | 2 | 3 | 8 | 4 | 8 | 9 | |||||
Accrued Liabilities Current | 25 | 20 | 19 | 15 | 11 | 13 | 9 | 8 | 10 | 12 | 10 | 10 | |||||
Liabilities Current | 81 | 67 | 65 | 38 | 30 | 39 | 33 | 42 | 65 | 32 | 31 | 35 | |||||
Long Term Line Of Credit | 41 | 41 | 40 | 41 | 22 | 22 | 24 | 24 | 14 | 14 | 14 | - | |||||
Other Liabilities Noncurrent | 1 | 0 | 1 | 1 | - | - | - | - | 0 | 0 | 0 | 1 | |||||
Liabilities | 122 | 108 | 106 | 80 | 53 | 61 | 58 | 66 | 79 | 46 | 46 | 36 | |||||
Stockholders Equity | |||||||||||||||||
Common Stock Value | - | - | - | - | - | 0 | 0 | 0 | - | 0 | - | - | |||||
Additional Paid In Capital Common Stock | 938 | 914 | 662 | 650 | 644 | 640 | 626 | 552 | 540 | 368 | 362 | 354 | |||||
Accumulated Other Comprehensive Income Loss Net Of… | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | |||||
Retained Earnings Accumulated Deficit | -660 | -583 | -532 | -465 | -422 | -399 | -364 | -350 | -345 | -290 | -266 | -248 | |||||
Stockholders Equity | 279 | 332 | 131 | 185 | 223 | 241 | 262 | 202 | 196 | 78 | 96 | 106 | |||||
Liabilities And Stockholders Equity | 401 | 440 | 237 | 265 | 275 | 302 | 320 | 268 | 276 | 125 | 142 | 142 | |||||
Common Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Shares Issued | 416 | 395 | 384 | 379 | 378 | 376 | 408 | 432 | 427 | 411 | 401 | 388 | |||||
Shares Outstanding | 104 | 99 | 77 | 76 | 76 | 75 | 82 | 72 | 71 | 41 | 40 | 39 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 4.27% | 93.75% | - | - | - | - | - | - | - | - | - | - |
| 2025 | 12.38% | 1.39% | 51.08% | 12.10% | -0.55% | 50.17% | 11.55% | 15.17% | 53.44% | 6.42% | 31.17% | 21.40% |
| 2024 | -8.43% | -24.97% | -2.24% | -9.79% | -15.48% | -6.83% | 8.64% | -9.04% | -7.05% | -6.35% | -5.75% | 10.44% |
| 2023 | - | - | - | -19.32% | -23.35% | -44.37% | 11.85% | 33.33% | 32.96% | 82.80% | 62.24% | 53.64% |
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 50+ calculated metrics
Subscribe to unlock 17+ years of data and 50+ calculated metrics
Performance and Valuation Metrics
Metrics | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Liquidity Ratios | |||||||||||||||||
| Current Ratio | 4.69 | 6.29 | 3.30 | 4.98 | 7.27 | 7.25 | 9.00 | 5.92 | 3.91 | 3.22 | 3.85 | 3.41 | |||||
| Quick Ratio | 4.60 | 6.17 | 3.20 | 4.82 | 6.97 | 7.05 | 8.88 | 5.81 | 3.87 | 3.09 | 3.78 | 3.33 | |||||
| Working Capital | 299.45M | 352.62M | 150.43M | 151.18M | 191.22M | 242.77M | 266.09M | 205.85M | 190.20M | 71.63M | 88.93M | 84.67M | |||||
Leverage & Debt | |||||||||||||||||
| Debt to Equity | 0.44 | 0.32 | 0.81 | 0.43 | 0.24 | 0.25 | 0.22 | 0.33 | 0.41 | 0.59 | 0.47 | 0.34 | |||||
| Interest Coverage TTM | -31.57 | -30.34 | -31.05 | -30.14 | -46.46 | -45.52 | -45.33 | -54.28 | -74.50 | -102.03 | -54.81 | -50.80 | |||||
| Debt Ratio | 0.31 | 0.24 | 0.45 | 0.30 | 0.19 | 0.20 | 0.18 | 0.25 | 0.29 | 0.37 | 0.32 | 0.25 | |||||
Efficiency & Turnover | |||||||||||||||||
| Asset Turnover TTM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
Per Share Metrics | |||||||||||||||||
| Diluted EPS TTM | -2.18 | -2.06 | -1.96 | -1.34 | -0.89 | -1.54 | -1.22 | -1.36 | -2.62 | -2.44 | -1.93 | -1.95 | |||||
| Free Cash Flow Per Share TTM | -1.33 | -1.47 | -1.33 | -1.19 | -1.08 | -1.12 | -0.95 | -1.03 | -1.41 | -1.64 | -1.43 | -1.28 | |||||
| Dividend Per Share TTM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
Growth Metrics | |||||||||||||||||
| Net Income Growth (1Y) | 206.01% | 69.12% | 71.88% | 12.23% | -38.06% | 13.52% | 27.39% | 35.45% | 98.41% | 68.55% | 47.94% | - | |||||
| EPS Growth (1Y) | 139.28% | 33.40% | 55.91% | -5.44% | -65.15% | -36.91% | -35.05% | -27.34% | 57.85% | 32.83% | 9.12% | - | |||||
Valuation Metrics | |||||||||||||||||
| P/E TTM | -8.66 | -6.51 | -6.02 | -4.84 | -6.41 | -4.51 | -4.53 | -5.08 | -3.59 | -1.50 | -1.62 | -1.83 | |||||
| P/B TTM | 7.37 | 3.60 | 7.75 | 2.99 | 2.23 | 2.03 | 1.69 | 2.57 | 2.29 | 1.83 | 1.30 | 1.30 | |||||
| Market Cap | 2.06B | 1.20B | 1.01B | 553.91M | 497.65M | 490.41M | 443.30M | 518.49M | 449.89M | 143.32M | 124.32M | 137.72M | |||||
| Enterprise Value | 1.79B | 938.26M | 992.63M | 520.51M | 414.79M | 216.67M | 148.02M | 275.36M | 197.56M | 43.61M | 6.62M | 20.82M | |||||
Calculated Values | |||||||||||||||||
| Free Cash Flow TTM | -144.77M | -131.56M | -113.94M | -101.56M | -91.95M | -79.13M | -74.34M | -73.78M | -67.63M | -64.37M | -56.65M | -49.32M | |||||
| Net Debt | -262.52M | -257.84M | -19.96M | -33.39M | -82.85M | -273.74M | -295.28M | -243.13M | -252.33M | -99.70M | -117.70M | -116.90M | |||||
Per-Share and Margin | |||||||||||||||||
| EPS TTM | |||||||||||||||||
| Adjusted EPS TTM | |||||||||||||||||
| Cash Flow Per Share TTM | |||||||||||||||||
| Pretax Margin TTM | |||||||||||||||||
| Stock Comp to Revenue TTM | |||||||||||||||||
Turnover Ratios and Averages | |||||||||||||||||
| Average Assets | |||||||||||||||||
| Average Equity | |||||||||||||||||
| Average Inventory | |||||||||||||||||
| Average Receivables | |||||||||||||||||
| Average Accounts Payables | |||||||||||||||||
| Inventory Turnover TTM | |||||||||||||||||
| Payables Turnover TTM | |||||||||||||||||
| Days Inventory Outstanding TTM | |||||||||||||||||
| Days Payables Outstanding TTM | |||||||||||||||||
| Cash Conversion Cycle TTM | |||||||||||||||||
| Working Capital to Revenue | |||||||||||||||||
| Deferred Revenue to Revenue | |||||||||||||||||
Growth Rates | |||||||||||||||||
| Total Assets Growth (1Y) | |||||||||||||||||
| Total Assets Growth (3Y) | |||||||||||||||||
| Total Assets Growth (5Y) | |||||||||||||||||
| Dividends Paid Growth (1Y) | |||||||||||||||||
| Dividends Paid Growth (3Y) | |||||||||||||||||
| Dividends Paid Growth (5Y) | |||||||||||||||||
| EPS Growth (3Y) | |||||||||||||||||
| EPS Growth (5Y) | |||||||||||||||||
| Net Income Growth (3Y) | |||||||||||||||||
| Net Income Growth (5Y) | |||||||||||||||||
| Net Profit Margin Growth (1Y) | |||||||||||||||||
| Net Profit Margin Growth (3Y) | |||||||||||||||||
| Net Profit Margin Growth (5Y) | |||||||||||||||||
| Net Revenue Growth (3Y) | |||||||||||||||||
| Net Revenue Growth (5Y) | |||||||||||||||||
| Deferred Revenue Growth (1Y) | |||||||||||||||||
| Retained Earnings Growth (1Y) | |||||||||||||||||
Credit, Liquidity, Returns, Payout | |||||||||||||||||
| Cash Ratio | |||||||||||||||||
| Net Working Capital | |||||||||||||||||
| Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to Equity | |||||||||||||||||
| Altman A | |||||||||||||||||
| Altman B | |||||||||||||||||
| Altman C | |||||||||||||||||
| Altman D | |||||||||||||||||
| Altman E | |||||||||||||||||
| Altman Z-Score | |||||||||||||||||
| ROA TTM | |||||||||||||||||
| ROE TTM | |||||||||||||||||
| NOPAT TTM | |||||||||||||||||
| ROIC TTM | |||||||||||||||||
| Effective Tax Rate TTM | |||||||||||||||||
| Payout Ratio TTM | |||||||||||||||||
| Dilution Ratio | |||||||||||||||||
| Retained Earnings to Equity | |||||||||||||||||
| Treasury Stock to Equity | |||||||||||||||||
| Treasury Stock Change (1Y) | |||||||||||||||||
| Accrued to Current Liabilities | |||||||||||||||||
Valuation Ratios | |||||||||||||||||
| P/CF TTM | |||||||||||||||||
| Dividend Yield TTM | |||||||||||||||||
| Free Cash Flow Yield TTM | |||||||||||||||||
| EV EBITDA TTM | |||||||||||||||||
| EV EBIT TTM | |||||||||||||||||
| Stock Compensation TTM | |||||||||||||||||
| Adjusted Net Income TTM | |||||||||||||||||
| Billings TTM | |||||||||||||||||
| Total Debt | |||||||||||||||||
| Invested Capital | |||||||||||||||||
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
Definium Therapeutics, Inc. (DFTX) — SEC Financial Statements & Analysis
Definium Therapeutics, Inc. (DFTX) is a medicinal chemicals & botanical products company, incorporated in A1. Definium Therapeutics, Inc. trades on DFTX: Nasdaq as: DFTX. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), Definium Therapeutics, Inc. reported a Debt-to-Equity ratio of 0.44x, a Price-to-Book (P/B) ratio of 7.37 (TTM), at a market cap of $2.06B. Figures below are sourced from SEC EDGAR, as-filed.
- Debt To Equity
- 0.44x
- P/B TTM
- 7.37
- Market Cap
- $2.06B
Data as of 2026-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Definium Therapeutics, Inc. in?
Definium Therapeutics, Inc. (DFTX) operates in the Medicinal Chemicals & Botanical Products industry.
What is DFTX's market cap?
Definium Therapeutics, Inc. (DFTX) has a market capitalization of $2.06B as of 2026-03-31.
What exchange does DFTX trade on?
Definium Therapeutics, Inc. (DFTX) trades on the DFTX: Nasdaq.
Where is Definium Therapeutics, Inc. incorporated?
Definium Therapeutics, Inc. is incorporated in British Columbia, Canada.